Thrombolytic effect of Subtilisin QK on carrageenan induced thrombosis model in mice

Journal of Thrombosis and Thrombolysis

Volumn 28, Issue 4, 2009, Pages 444-448

  Yan, Feng ^a,b   Yan, Junpeng ^b   Sun, Weiting ^b   Yao, Lunguang ^c   Wang, Jiancheng ^c   Qi, Yipeng ^b   Xu, Hua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN UNIVERSITY   (China)

^c NANYANG NORMAL UNIVERSITY   (China)

Author keywords

Fibrinolytic enzyme; Subtilisin QK; Thrombolytic activity; Thrombosis model; Thrombus

Indexed keywords

CARRAGEENAN; FIBRIN; SUBTILISIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; DRUG EFFICACY; FIBRINOLYSIS; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; THROMBOSIS;

ANIMALS; CARRAGEENAN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; HUMANS; MALE; MICE; SUBTILISINS; THROMBOSIS;

EID: 70350532503     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-009-0333-3     Document Type: Article

References (23)

1. Hsiao G, Yen MH, Lee YM, Sheu JR (2002) Antithrombotic effect of PMC, a potent alpha-tocopherol analogue on platelet plug formation in vivo. Br J Haematol 117:699-704. doi: 10.1046/j.1365-2141.2002.03492.x
2. Jorgensen L (2006) The role of platelets in the initial stages of atherosclerosis. J Thromb Haemost 4:1443-1449. doi: 10.1111/ j.1538-7836.2006.02006.x
3. Boisseau MR (1997) Venous valves in the legs: Hemodynamic and biological problems and relationship to physiopathology. J Mal Vasc 22:122-127
4. Selwyn A (2003) Prothrombotic and antithrombotic pathways in acute coronary syndromes. Am J Cardiol 91(12):3-11. doi: 10.1016/ S0002-9149(03)00428-4
5. Plow EF, Hoover-Plow J (2004) The functions of plasminogen in cardiovascular disease. Trends Cardiovasc Med 14:180-186. doi: 10.1016/ j.tcm.2004.04.001
6. Ko JH, Yan JP, Zhu L, Qi YP (2004) Identification of two novel fibrinolytic enzymes from Bacillus subtilis QK02. Comp Biochem Physiol C Toxicol Pharmacol 137:65-74. doi: 10.1016/j.cca.2003.11.008
7. Ko J, Yan J, Zhu L, Qi Y (2005) Subtilisin QK, a fibrinolytic enzyme, inhibits the exogenous nitrite and hydrogen peroxide induced protein nitration, in vitro and in vivo. J Biochem Mol Biol 38:577-583
8. Verbeuren TJ (2006) Experimental models of thrombosis and atherosclerosis. Therapie 61:379-387. doi: 10.2515/therapie:2006069
9. Bekemeier H, Hirschelmann R, Giessler AJ (1984) Carrageenan-induced thrombosis in the rat and mouse as a test model of substances influencing thrombosis. Biomed Biochim Acta 43(8-9):S347-S350
10. Bekemeier H, Hirschelmann R, Giessler AJ (1985) Carrageenin-induced thrombosis in rats and mice: A model for testing antithrombotic substances? Agents Actions 16:449-451. doi: 10.1007/BF01982887
11. Kod'ousek R, Jezdinsk J, Krajci D (2007) Histological and ultrastructural changes of cardiomyocytes in experimental rats with tail thrombosis following subplantar application of carrageenin. Med Princ Pract 16:360-366. doi: 10.1159/000104809
12. Hansra P, Moran EL, Fornasier VL, Bogoch ER (2000) Carrageenan-induced arthritis in the rat. Inflammation 24:141-155. doi: 10.1023/ A:1007033610430
13. Gervasi GB, Bartoli C, Carpita G (1991) A new low molecular weight heparan sulphate antagonizes kappa-carrageenan-induced thrombosis in rats. Pharmacol Res 24:59-63. doi: 10.1016/1043-6618(91)90065-6
14. Hirschelmann R, Bekemeier H (1986) Heparin and phenprocoumon inhibit kappa-carrageenan induced thrombosis in rats. Folia Haematol Int Mag Klin Morphol Blutforsch 113:379-382
15. Hu S, Tian Q, Gu J, Sha J, Zhao D, Yan P et al (1993) A new kind of thrombus formation animal model in vivo. Zhonghua Xue Ye Xue Za Zhi 14:541-542
16. Astrup T, Mullertz S (1952) The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys 40:346-351. doi: 10.1016/ 0003-9861(52)90121-5
17. Di Rosa M (1972) Biological properties of carrageenan. J Pharm Pharmacol 24:89-102
18. Liang AH, Ding XS, Li W, Xue BY, Wang JH, Yang HJ (2005) Development of an animal model of blood stasis syndrome and thrombosis. Zhongguo Zhong Yao Za Zhi 30:1613-1616
19. Elsayed YA, Nakagawa K, Kamikubo YI, Enjyoji KI, Kato H, Sueishi K (1996) Effects of recombinant human tissue factor pathway inhibitor on thrombus formation and its in vivo distribution in a rat DIC model. Am J Clin Pathol 106:574-583
20. Bertelli A, Bertelli AA, Giovannini L (1994) The potentiating effect of propionyl carnitine on prostacycline prevention of thrombosis induced by endothelin (ET-1) and K-carrageenan. Drugs Exp Clin Res 20:7-11
21. Bekemeier H, Gabor M, Hirschelmann R (1990) Influence of flavonoids and lanthanides on kappa-carrageenan rat tail thrombosis. Exp Pathol 40:61-63
22. Wang LL, Li ZC, Mei QB, Zhao DH (2000) MN9202 protection of tail artery in carrageenan induced thrombos is rats. J Fourth Mil Med Univ 21(2):214-216; Chinese
23. Yan JP, Ko JH, Qi YP (2004) Generation and characterization of a novel single-chain antibody fragment specific against human fibrin clots from phage display antibody library. Thromb Res 114:205-211. doi: 10.1016/ j.thromres.2004.06.013